ML218 is primarily investigated for its potential in neuroscience research, particularly as a selective antagonist of the TRPC4/TRPC5 ion channels. These channels are implicated in various neurological disorders, making ML218 a valuable tool for studying their role in conditions such as anxiety, depression, and epilepsy. Researchers use ML218 to explore the mechanisms underlying these disorders and to evaluate its potential as a therapeutic agent. Additionally, ML218 helps in understanding the physiological functions of TRPC4/TRPC5 channels in the central nervous system, contributing to the development of targeted treatments for related diseases. Its application extends to preclinical studies, where it aids in identifying novel drug candidates for neurological and psychiatric conditions.